morpho-functional evaluation of eye disease with corneal neovascularitation after subconjuctival injection of bevacizumab. Interventional pilot study. - ND
- Conditions
- disease with corneal neovascularizationMedDRA version: 12.0Level: LLTClassification code 10055665Term: Corneal neovascularisation
- Registration Number
- EUCTR2007-003253-88-IT
- Lead Sponsor
- POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
eye disease with severe corneal neovascularization over 18 years old visual acuity ranger for count finger to 0,5
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
ocular infection in progress retinal detachment or severe retinopathy glaucoma severe immunodepression diabetic decompensation high systemic thrombosis risk
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: to evaluate efficacy and safety of topical bevacizumab in the therapy of corneal neovascularization. to restore corneal transparency and avasculariry and to improve visual acuity;Secondary Objective: and to improve visual acuity;Primary end point(s): to reduce corneal neovascularization
- Secondary Outcome Measures
Name Time Method